Published:
August 06, 2021
Coverage:
Accelerating Materials Innovation More...
Topics:
Activities:
Markets More...
Further Reading
Phytolon grabs $4.1 million in funding for its fermentation-based colorants platform
News Commentary | September 18, 2020
This is the second funding round for a fermentation‑based colorants platform in a matter of weeks, the first going to Chromologics. While Chromologics is focused on pigments in the red to yellow portion of the visible spectrum, Phytolon claims to go beyond that to include colors like purple. Even as... Not part of subscription
The latest synbio buzz: bee-free honey
News Commentary | October 09, 2020
Berkeley spinout MeliBio, backed by Big Idea Ventures, uses synbio to replicate the bioprocess bees use to make honey from nectar, but in an industrial bioreactor. While threats to bee populations might make alternatives to honey attractive or even necessary, normal honey production itself doesn't ... Not part of subscription
Brightseed forms alliance with Pharmavite for phytonutrient discovery
News Commentary | November 25, 2020
This adds to Brightseed's growing momentum, having also announced a partnership with Danone and closing a $27 million funding round in the past six months. In an interview with both companies, Pharmavite revealed that identifying ingredients for sleep will be an initial focus area. When and how ... To read more, click here.
by Xiao Zhong
Zymergen went public on Earth Day this year and promised to generate sales of its first product, Hyaline, in H2 2021. Now it has pushed the target to 2022, and apparently, the public market has not responded well. As discussed in the key issue section of Genomatica's profile, Zymergen is essentially a new materials company based on its platform, and it not only has to develop and productize a material but also needs to develop the market for it. While one can't rule out the possibility of Zymergen creating hype around Hyaline to attract public investors, these kinds of delays should be expected, as materials development is, in essence, hard. Yet, building your own product is still the high-risk, high-reward approach.
For the original news article, click here .